ResAppDx empowers clinicians to remotely assess respiratory disease with confidence
Coviu has partnered with ResApp Health to facilitate remote respiratory testing using the ResAppDx app to help clinicians assess a patient’s respiratory symptoms and accurately diagnose their illness.
Remote respiratory smartphone testing
Clinically validated, TGA approved medical device
Patients take the ‘cough test’ using the ResAppDx app to aid you in your diagnosis of common respiratory diseases.
Results proven in large Australian clinical studies. Read our scientific publications.
Analysis report available during the session to help you confidently assess patient’s symptoms.
Remote Respiratory Testing for Patients
Perform Respiratory Cough Test
Join the Call
Patients are asked if they are experiencing these symptoms: fever, coughing, difficulty breathing, shortness of breath, runny nose, sore throat.
Patients take the test using the ResAppDx app to capture five coughs.
Their coughs are instantly analysed.
Patients will then speak with their doctor to discuss the test results.
Frequently Asked Questions
ResAppDx can assist clinicians in the diagnosis of lower respiratory tract disease, pneumonia, asthma / reactive airway disease exacerbations, COPD exacerbations*, croup and bronchiolitis (2 years and younger).
*Available on iOS only
There is no additional cost to the clinic. The test is funded by the patient.
Once the add-on is installed, a symptom and device check will appear for all your patients who receive the email link to join your call. Patients who indicate that they are experiencing respiratory related symptoms will be guided to download the ResAppDx app and complete the test.
To patients, the ResAppDx Respiratory Test is referred to as a ‘cough test’.
Patients who are 29 days or older.
The patient will be charged $11.00 per cough test.
Medicare does not cover the cost of this testing.
The patient takes the cough test prior to the appointment (no earlier than one hour before the appointment). The results will be available to you (the Clinician) at the start of the session. This will allow more time spent with your patient discussing the results and treatment advice.
No. The ResAppDx Analysis Report is only made available to the clinician conducting the telehealth consultation. It is available in the ResAppDx respiratory drawer in the session.
Please refer to the Instructions for Use for more information. This will be available in theesAppDx Analysis Report.
For more information on scientific presentations and publications visit https://www.resapphealth.com.au/technology/#pubs
The ResAppDx app is compatible with iPhone (except iPhone 12 models) and Samsung Galaxy S9, S10 and S20 (except the Plus and Ultra variants).
Disclaimer: Only indicated for use on patients aged 29 days and older. The result of the test should not be used as a sole diagnosis. The result should be used as part of an overall clinical assessment of the patient. Please refer to the Instructions for Use for information on interpreting the results and the clinical performance of ResAppDx. ResAppDx is listed on the Australian Register of Therapeutic Goods (ARTG). Always follow and read the Instructions for Use.